Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Day One Biopharmaceuticals (DAWN) over the last 5 years, with Dec 2024 value amounting to $100.8 million.

  • Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) rose 16.72% to $102.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.4 million, marking a year-over-year increase of 16.72%. This contributed to the annual value of $100.8 million for FY2024, which is 15.86% up from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) is $100.8 million, which was up 15.86% from $87.0 million recorded in FY2023.
  • Day One Biopharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $100.8 million during FY2024, with a 5-year trough of $60.3 million in FY2020.
  • In the last 3 years, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $87.0 million in 2023 and averaged $87.1 million.
  • Data for Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY rose of 18.76% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) stood at $60.3 million in 2020, then rose by 2.64% to $61.9 million in 2021, then increased by 18.76% to $73.5 million in 2022, then increased by 18.35% to $87.0 million in 2023, then grew by 15.86% to $100.8 million in 2024.